DHR · Q2 2026

Archived report (Q2 2026). Latest deep dive →

US GAAP, Q2 2026 · quarter ended 06/26/2026 · released Jul 21

The quarter in brief

Better than feared — sales +5.5% to $6.27B with core growth improving to +3.0% (+4.5% excluding respiratory testing) and Life Sciences posting its strongest quarter in years; the +57% jump in net earnings is mostly the base effect of last year's $432M trade-name impairment, while adjusted EPS grew a more honest 8% to $1.94.

Net Earnings

$870M

up 56.8% y/y

Sales

$6,265M

up 5.5% y/y

Operating Profit

$1,127M

up 48.3% y/y

Gross Profit

$3,611M

up 2.5% y/y

All figures in $M.

Sankey diagram of DHR earnings report for Q2 2026: revenue, costs and profit
Line item	Amount and change
Sales	$6,265 · +5.5%
Cost of Sales	$2,654 · +10.0%
Gross Profit	$3,611 · +2.5% · 57.6% margin (was 59.4%)
SG&A	$2,072 · −12.2% · year ago incl. $432M impairment
R&D	$412 · +2.2%
Operating Profit	$1,127 · +48.3% · 18.0% margin
Net Interest & Other Expense	$49 · vs $105 · interest expense $107, income $61
Pre-Tax Income	$1,078 · +64.6%
Income Tax	$208 · +108% · 19.3% rate
Net Earnings	$870 · +56.8% · $1.23/sh · 13.9% margin

Verdict: better than feared — sales +5.5% to $6.27B with core growth improving to +3.0% (+4.5% excluding respiratory testing) and Life Sciences posting its strongest quarter in years; the +57% jump in net earnings is mostly the base effect of last year's $432M trade-name impairment, while adjusted EPS grew a more honest 8% to $1.94.

Full-year 2026: core revenue growth 3.0–4.0%, adjusted diluted EPS raised to $8.45–8.60 (was $8.35–8.55) after the Masimo acquisition closed earlier than expected; Q3 core growth guided at 2.0–3.0%. Operating cash flow $1.5B, free cash flow $1.3B in the quarter.

Source and notation

Source: Danaher press release, 8-K EX-99.1 of 07/21/2026 (SEC EDGAR).

Sankey diagram of DHR earnings report for Q2 2026: revenue, costs and profit — Open as an image: DHR, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line

Chart: “DHR Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/dhr/q2-2026. Licensed under CC BY 4.0.

HTML: image with link and credit

<figure>
  <a href="https://whoreportstoday.com/t/dhr/q2-2026"><img src="https://whoreportstoday.com/t/dhr/q2-2026/sankey.png" alt="DHR Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/dhr/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>

Direct link to the image (PNG)

https://whoreportstoday.com/t/dhr/q2-2026/sankey.png

Link for your article text

<a href="https://whoreportstoday.com/t/dhr/q2-2026">DHR Q2 2026 earnings chart (Who Reports Today)</a>

This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

DHR — Danaher Corporation is a diversified technology company focused on science and technology solutions for industrial and healthcare sectors.

It operates through various subsidiaries in areas like life sciences, diagnostics, and environmental testing.

More reports: DVA · Q2 2026 · DXCM · Q2 2026 · ELV · Q3 2026 · EW · Q2 2026 · GEHC · Q2 2026 · GILD · Q2 2026 · HCA · Q2 2026 · HSIC · Q2 2026 · HUM · Q2 2026 · IDXX · Q2 2026 · all reports

DHR · Q2 2026

Company reports